Ke Yang1, Hao Wang, Zhiyong Liang, Jun Liang, Fang Li, Yansong Lin. 1. From the *Department of Nuclear Medicine, Pecking Union Medical College Hospital, Beijing; †Department of Oncology, the Affiliated Hospital of Qingdao University Medical College, Qingdao; and ‡Department of Pathology, Pecking Union Medical College Hospital, Beijing, China.
Abstract
PURPOSE: It was reported that BRAF mutation correlates with radioactive iodine refractory papillary thyroid carcinoma (PTC) in local recurrence, whereas its relationship with I uptake status in distant metastatic PTC remains uncertain. This prospective study tried to explore the association between I uptake in distant metastases (DM) of PTC and BRAF mutation status in their primary tumor. METHODS: Seventy-three patients with DM were divided into BRAF mutation group (n = 19) and wild-type BRAF group (n = 54) according to the BRAF mutation status. After posttherapy I whole-body scan was performed, the relation between I uptake in DM, BRAF mutation status, and clinicopathological characteristics of 2 groups were compared. RESULTS: The mean age of mutation group was older than that of the wild-type group (P < 0.05). In the mutation group, 16 patients (84.2%, 16 of 19) were found to be with non-iodine-avid DM, whereas in wild-type group, only 5.6% (3 of 54) were with non-iodine-avid DM. The sensitivity and specificity of using BRAF mutation for the identification of non-iodine-avid DM were 84.2% and 94.4%, respectively. CONCLUSIONS: BRAF mutation in primary tumor might be a promising molecular marker to predict the status of I uptake in distal metastases.
PURPOSE: It was reported that BRAF mutation correlates with radioactive iodine refractory papillary thyroid carcinoma (PTC) in local recurrence, whereas its relationship with I uptake status in distant metastatic PTC remains uncertain. This prospective study tried to explore the association between I uptake in distant metastases (DM) of PTC and BRAF mutation status in their primary tumor. METHODS: Seventy-three patients with DM were divided into BRAF mutation group (n = 19) and wild-type BRAF group (n = 54) according to the BRAF mutation status. After posttherapy I whole-body scan was performed, the relation between I uptake in DM, BRAF mutation status, and clinicopathological characteristics of 2 groups were compared. RESULTS: The mean age of mutation group was older than that of the wild-type group (P < 0.05). In the mutation group, 16 patients (84.2%, 16 of 19) were found to be with non-iodine-avid DM, whereas in wild-type group, only 5.6% (3 of 54) were with non-iodine-avid DM. The sensitivity and specificity of using BRAF mutation for the identification of non-iodine-avid DM were 84.2% and 94.4%, respectively. CONCLUSIONS:BRAF mutation in primary tumor might be a promising molecular marker to predict the status of I uptake in distal metastases.
Authors: Ralf Paschke; Thomas Lincke; Stefan P Müller; Michael C Kreissl; Henning Dralle; Martin Fassnacht Journal: Dtsch Arztebl Int Date: 2015-06-26 Impact factor: 5.594
Authors: Myat Han Soe; Janet M Chiang; Robert R Flavell; Elham Khanafshar; Laura Mendoza; Hyunseok Kang; Chienying Liu Journal: J Clin Endocrinol Metab Date: 2022-07-14 Impact factor: 6.134
Authors: Ryan K Orosco; Elamprakash N Savariar; Philip A Weissbrod; Julio A Diaz-Perez; Michael Bouvet; Roger Y Tsien; Quyen T Nguyen Journal: J Surg Oncol Date: 2016-01-12 Impact factor: 3.454
Authors: Elyse K Hanly; Neha Y Tuli; Robert B Bednarczyk; Robert Suriano; Jan Geliebter; Augustine L Moscatello; Zbigniew Darzynkiewicz; Raj K Tiwari Journal: Oncotarget Date: 2016-02-23